Combination therapy for advanced and metastatic kidney cancer Review

  


Authors: Lee, C. H.; Motzer, R. J.
Review Title: Combination therapy for advanced and metastatic kidney cancer
Abstract: The treatment of metastatic kidney cancer is rapidly evolving with the shift from immune checkpoint inhibitor monotherapy to combination therapy. In 2018, the combination of nivolumab–ipilimumab received regulatory approval and multiple positive clinical trials were reported with combinations of PD-1 or PD-L1 inhibitors in conjunction with antiangiogenic drugs. © 2018, Springer Nature Limited.
Journal Title: Nature Reviews Urology
Volume: 16
Issue: 2
ISSN: 1759-4812
Publisher: Nature Publishing Group  
Date Published: 2019-02-01
Start Page: 77
End Page: 78
Language: English
DOI: 10.1038/s41585-018-0133-7
PUBMED: 30538301
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058441470&doi=10.1038%2fs41585-018-0133-7&partnerID=40&md5=561c22dabd9f4130b2d2bf04a50776d7
Notes: Note -- Export Date: 1 March 2019 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer
  2. Chung-Han Lee
    157 Lee
Related MSK Work